RecruitingNCT06065228

Therapeutic Endpoint in Pediatric IBD Conditions

Development of a Therapeutic Endpoint in Pediatric IBD Conditions


Sponsor

Children's National Research Institute

Enrollment

60 participants

Start Date

Nov 27, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this clinical study is the development of physiologic endpoint of inflammation in pediatric patients diagnosed with inflammatory bowel disease (IBD), specifically subtypes Crohn's disease (CD) and ulcerative colitis (UC). The novel medical device evaluates the patient's sensory response to each of the three sensory nerve fiber types. Data from the device provides an assessment of disease activity and a more precise approach to treatment.


Eligibility

Min Age: 6 YearsMax Age: 21 Years

Inclusion Criteria2

  • Male or female ≥ 6 years of age at screening.
  • Documentation of an IBD diagnosis as evidenced by history

Exclusion Criteria2

  • Documented history of eye disease precluding pupillometry
  • Patients who are unwilling or unable to participate due to developmental delays or ongoing psychological diagnoses.

Interventions

OTHERAlgometRx Nociometer

Physiologic characterization of disease activity


Locations(1)

Children's National Health System

Washington D.C., District of Columbia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06065228


Related Trials